Nicotine and Parkinson's disease: implications for therapy.
about
Multiple roles for nicotine in Parkinson's diseaseInsights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutationsNicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationA genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder.Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats.Nicotine from cigarette smoking and diet and Parkinson disease: a review.Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.Nicotine as a potential neuroprotective agent for Parkinson's disease.Recent advances in treating Parkinson's disease.Gene-environment interactions in Parkinson's disease: the importance of animal modeling.A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smokingPositive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasProminent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatmentNicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseChronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway.Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function α6* nAChRs.Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.Targeting nicotinic receptors for Parkinson's disease therapy.Can nicotine be used medicinally in Parkinson's disease?Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.Nicotine promotes survival of cells expressing amyloid precursor protein and presenilin: implication for Alzheimer's disease.Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's diseaseToxic effects of low alcohol and nicotine combinations in SH-SY5Y cells are apoptotically mediated.Genetic Factors for Enhancement of Nicotine Levels in Cultivated Tobacco.Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.Smoking and outcome of traumatic brain injury.Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson's disease.
P2860
Q22252514-528C8C70-B57C-44BE-8A7D-2647A61D0E83Q30448803-934A15AC-8D51-4B5C-A5CB-DA60059A35D3Q30475334-EF22DF34-AEA9-4FF9-A061-A25E6326B0ABQ30531483-31074634-D101-4696-A209-114FF41BA080Q33526671-3E5356BD-B496-431E-A642-35F68C004CCCQ33624583-431BCA3A-1F4E-445B-819A-134C5ACD3853Q33862534-A113D54A-63F1-4BB4-89B1-461634583A2EQ34111402-1F9351FB-A40B-49BB-9243-419F0A3E3EC7Q34281003-EDD65CBD-5249-4DFA-83BE-C935F94A3F67Q34554401-650FE54E-6E7F-4A2E-8B8A-5F84B8F5C1ADQ34898429-070CB324-5A8D-4F70-A907-BFEF10165F9BQ35161661-0FEFBA01-DA08-4CE5-9406-A323710DA019Q36039402-EA4F6535-9F13-4A61-BBB3-4D287BB6E316Q36079677-3E996352-4CD9-45ED-858B-DF976D26425CQ36880148-CCBFB5E3-5884-4D0A-AD2A-4F50B4DE7DDDQ37199162-4F0E94CB-0121-4449-8BB0-345E4A8B34F4Q37209730-B785D0F8-B225-4FAF-92E7-39AA523548FDQ37454529-BCC2E991-D396-4D9D-B3A1-9D66A05EAC2CQ37508589-EE2D8BB7-949B-4144-ACF6-5662915F8236Q37692812-3D4E6AB1-D026-4958-AA48-7F03A31FC705Q37800819-0385F2F0-EEB5-4727-906E-7B83132CC9B1Q37890986-740DA6CC-0D49-43AF-80C9-C62B8EFF06E8Q37916643-2758F6B0-A13E-4864-BADF-54DCBC61E618Q37960523-EF3B5B2C-FE53-4680-9A9B-45FFCCE6DBAAQ38209988-7C1B46DD-4513-44DF-A5A8-3524D88C62C4Q38428967-5735CB4F-7E53-4DC9-921D-958E3EA2EBB1Q38811387-A1B3C226-DF67-4981-9862-F5B1FF71A25FQ38941557-4FB8B56A-CD1F-454A-AA3B-F04E94FAC98AQ39211777-E4FCD47D-D2DC-40E9-BAD2-6F42378C2E0DQ39360051-8E0070B5-9A95-4BBE-92D3-9AFC2786ACF4Q39609418-8ED53DD5-6607-4A1E-9578-06105B0FE786Q40253033-9C3BD6D5-1F8D-4BF7-BEAD-EF32128DBDE9Q45928216-3C586A08-0ADE-426F-813C-49FA699966CDQ50730278-225DF1DF-C4C4-4E0E-B16A-00297ED0AA79Q50913570-9DFD205E-E16D-431D-AD1C-C9BC42E5FBA6
P2860
Nicotine and Parkinson's disease: implications for therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Nicotine and Parkinson's disease: implications for therapy.
@ast
Nicotine and Parkinson's disease: implications for therapy.
@en
type
label
Nicotine and Parkinson's disease: implications for therapy.
@ast
Nicotine and Parkinson's disease: implications for therapy.
@en
prefLabel
Nicotine and Parkinson's disease: implications for therapy.
@ast
Nicotine and Parkinson's disease: implications for therapy.
@en
P2860
P50
P356
P1433
P1476
Nicotine and Parkinson's disease: implications for therapy.
@en
P2860
P304
P356
10.1002/MDS.21900
P4011
4a87d353a1672504c617fe0415e7a30d713f185a
P407
P577
2008-09-01T00:00:00Z